NDT Advance Access originally published online on August 25, 2006
Nephrology Dialysis Transplantation 2007 22(1):289-290; doi:10.1093/ndt/gfl498
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer
Email: wolfgang.hilbe@uibk.ac.at
| The first 10% of the full text of this article appears below. |
Sir,
Management of localized stage III non-small cell lung cancer (NSCLC) patients has improved significantly in recent years. Nevertheless, there exist few case reports about chemotherapeutic regimens of patients with end-stage renal disease (ESRD) and NSCLC [1,2]. Docetaxel (DXL) in combination with carboplatin is successfully used in the
1Innsbruck Medical University
Clinical Division of Nephrology
Innsbruck
2Vienna Medical University
Department of Clinical Pharmacy and Diagnostics
Vienna
3Innsbruck Medical University
Clinical Division of General Internal Medicine
Innsbruck
Austria